An Official Website of the United States Government
Company Information:
Name:
WOOMERA THERAPEUTICS, INC.
Address:
115 ETNA RD, STE D
LEBANON, NH 03766-
LEBANON, NH 03766-
Located in HUBZone:
No
Woman-Owned:
No
Minority-Owned:
No
URL:
N/A
Phone:
N/A
Award Totals:
Award List:
MAG-1 Targeting of GRSA on Breast Cancer
Award Year / Program / Phase:
2006 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Roy H. Pang
Award Amount:
$100,000.00
Abstract:
DESCRIPTION (provided by applicant): The objective of this project is to utilize different forms of a mouse monoclonal antibody, mMAG-1, not only to direct successful imaging of breast cancer but also to develop more rational approaches to treatment. The hypothesis being tested is that… More
Treatment of Breast Cancer with MAG-1 Antibody
Award Year / Program / Phase:
2009 / SBIR / Phase II
Agency:
HHS
Principal Investigator:
Roy H. Pang
Award Amount:
$688,433.00
Abstract:
DESCRIPTION (provided by applicant): The objective of this project is to utilize a monoclonal antibody, MAG-1, to develop new, rational, and successful treatment of breast cancer. The hypothesis being tested is that Glycopeptide-Related cell-Surface Antige
n (GRSA) will provide a sensitive and… More
Targeted Treatment of Recurrent Small Cell Lung Cancer with Anti-AbnV2 Antibodies
Award Year / Program / Phase:
2011 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Roy H. Pang – 603-448-5511
Award Amount:
$100,001.00
Abstract:
DESCRIPTION (provided by applicant): The objective of this Phase 1 project is to improve an effective treatment of recurrent small-cell lung cancer (rSCLC) by targeting a tumor-specific abnormal receptor, AbnV2 that is a surface-marker of the disease. Currently, there is no effective treatment for… More
Targeted Treatment of Recurrent Small Cell Lung Cancer with Anti-AbnV2 Antibodies
Award Year / Program / Phase:
2012 / SBIR / Phase II
Agency:
HHS
Principal Investigator:
Roy H. Pang – 603-448-5511
Award Amount:
$986,459.00
Abstract:
DESCRIPTION (provided by applicant): There is currently no effective treatment for recurrent small-cell lung cancer (rSCLC). The objective of this project is to utilize a monoclonal antibody, Abner, to develop new, rational, and successful treatment of rSCLC. The hypothesis being tested is that an… More